Skip to content

A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-526304-79-00
Enrollment
787
Registered
2026-07-29
Start date
Unknown
Completion date
Unknown
Last updated
2026-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF); on background SGLT2i.

Brief summary

Time to first occurrence of any component of the composite of cardiovascular (CV) death, hospitalization for heart failure (HHF), or urgent heart failure (HF) visit.

Detailed description

1. Total number of HF events (first and recurrent; HHF and urgent HF visit)., 2. Change from baseline to Week 52 in a prespecified heart failure patient‑reported outcome total score among participants with baseline value below a prespecified threshold., 3. Time to first occurrence of composite of all cause death, HHF, myocardial infarction (MI), or stroke (4point MACE).

Interventions

DRUGForxiga 10 mg film-coated tablets

Sponsors

AstraZeneca AB
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Time to first occurrence of any component of the composite of cardiovascular (CV) death, hospitalization for heart failure (HHF), or urgent heart failure (HF) visit.

Secondary

MeasureTime frame
1. Total number of HF events (first and recurrent; HHF and urgent HF visit)., 2. Change from baseline to Week 52 in a prespecified heart failure patient‑reported outcome total score among participants with baseline value below a prespecified threshold., 3. Time to first occurrence of composite of all cause death, HHF, myocardial infarction (MI), or stroke (4point MACE).

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 31, 2026